Crossmark

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

Crossref DOI link: https://doi.org/10.1038/cdd.2016.35

Published Online: 2016-04-15

Published Print: 2016-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamazaki, T

Pitt, J M

Vétizou, M

Marabelle, A

Flores, C

Rekdal, Ø

Kroemer, G

Zitvogel, L
License Information

Text and Data Mining valid from 2016-04-15
More Information

Article History

Received: 7 December 2015

Revised: 29 February 2016

Accepted: 8 March 2016

First Online: 15 April 2016

Competing interests

: The authors declare no conflict of interest.